62 related articles for article (PubMed ID: 10969588)
1. [Cost-effectiveness of cancer therapy].
Hisashige A
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1347-53. PubMed ID: 10969588
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
3. Health economics of care for patients with cancer and intractable disease in Japan.
Hisashige A; Katayama T; Mikasa H
Support Care Cancer; 1998 Nov; 6(6):503-10. PubMed ID: 9833298
[TBL] [Abstract][Full Text] [Related]
4. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
5. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
6. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
7. A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia.
Pickard AS; Topfer LA; Feeny DH
J Natl Cancer Inst Monogr; 2004; (33):102-25. PubMed ID: 15504922
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
Lyman GH; Kuderer NM
Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
[TBL] [Abstract][Full Text] [Related]
9. [Amendment of tuberculosis prevention law and prospect of tuberculosis control program].
Ushio M
Kekkaku; 2005 Jul; 80(7):541-6. PubMed ID: 16167781
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
12. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
13. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
14. How to interpret a healthcare economic analysis.
Brown MM; Brown GC
Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
[TBL] [Abstract][Full Text] [Related]
15. Cancer screening and health system resilience: keys to protecting and bolstering preventive services during a financial crisis.
Martin-Moreno JM; Anttila A; von Karsa L; Alfonso-Sanchez JL; Gorgojo L
Eur J Cancer; 2012 Sep; 48(14):2212-8. PubMed ID: 22424881
[TBL] [Abstract][Full Text] [Related]
16. [Cancer and health economics].
Koinuma N
Gan To Kagaku Ryoho; 1996 Jan; 23(1):1-7. PubMed ID: 8546457
[TBL] [Abstract][Full Text] [Related]
17. Why do we need cancer information?
Watanabe S
Jpn J Clin Oncol; 1990 Mar; 20(1):7-15. PubMed ID: 2181174
[TBL] [Abstract][Full Text] [Related]
18. Assessing the need for quality-adjusted cost-effectiveness studies of nanotechnological cancer therapies.
Bosetti R; Marneffe W; Vereeck L
Nanomedicine (Lond); 2013 Mar; 8(3):487-97. PubMed ID: 23477338
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the factors increasing medical expenses of the National Health Insurance].
Sugimoto R
Hokkaido Igaku Zasshi; 1991 May; 66(3):258-67. PubMed ID: 1885154
[No Abstract] [Full Text] [Related]
20. Proposal for the breakdown of increased cancer healthcare cost and its improvement.
Koinuma N
Jpn J Clin Oncol; 2013 Apr; 43(4):351-6. PubMed ID: 23423810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
